

CITATION REPORT

List of articles citing

Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies

DOI: 10.1161/jaha.113.000062

Journal of the American Heart Association, 2013, 2, e000062.

Source: <https://exaly.com/paper-pdf/56390477/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
283	Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (sIa _N) ⁺ dendritic cells and macrophages. 2013 , 132, 1184-1193.e8		37
282	Addressing Comorbid Diseases in Patients with Moderate-to-Severe Psoriasis. 2013 , 19a, 182-186		
281	Psoriasis and risk of heart failure: a nationwide cohort study. 2014 , 16, 743-8		50
280	Psoriasis: to treat or to manage?. 2014 , 23, 705-9		46
279	Psoriasis and risk of venous thromboembolism: a systematic review and meta-analysis. 2014 , 107, 793-7		37
278	Upgrading psoriasis responsibly. 2014 , 23, 710-1		4
277	Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. 2014 , 28, 1661-9		31
276	Psoriasis and comorbidities: links and risks. 2014 , 7, 119-32		85
275	Ustekinumab for the treatment of psoriatic arthritis. 2014 , 7, 111-21		2
274	Psoriasis: the visible killer. 2014 , 33, 95-9		7
273	Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES). 2014 , 28, 1109-12		22
272	Levels of physical activity in patients with severe psoriasis: a cross-sectional questionnaire study. 2014 , 15, 129-35		28
271	Psoriasis: The visible killer. 2014 , 33, 95-99		5
270	Anti-psoriatic therapy recovers high-density lipoprotein composition and function. 2014 , 134, 635-642		56
269	The year in acute coronary syndrome. 2014 , 63, 201-14		13
268	Increased prevalence of psoriasis in patients with coronary artery disease: results from a case-control study. <i>British Journal of Dermatology</i> , 2014 , 171, 580-7	4	13
267	Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: is psoriasis associated with atherosclerosis?. 2014 , 71, 642-8		37

266	Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. 2014 , 130, 837-44		176
265	Preventing Heart Failure in Inflammatory and Immune Disorders. 2014 , 8, 1		5
264	Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. 2015 , 34, 613-616		5
263	Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients. <i>PLoS ONE</i> , 2015 , 10, e0144335	3.7	16
262	Management of moderate to severe psoriasis in patients with metabolic comorbidities. <i>Frontiers in Medicine</i> , 2015 , 2, 1	4.9	56
261	Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. 2015 , 151, 161-9		60
260	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. 2015 , 386, 552-61		279
259	Psoriasis. 2015 , 386, 983-94		1181
258	Psoriasis Therapy in the Geriatric Population. 2015 , 65-69		2
257	Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies. 2015 , 5, 777-791		1
256	Psoriasis strikes back! Epicardial adipose tissue: another contributor to the higher cardiovascular risk in psoriasis. 2015 , 34, 613-6		9
255	Psoriasis: in between the skin and the fat. 2015 , 24, 181-2		4
254	Effect of tonsillectomy on psoriasis: a systematic review. 2015 , 72, 261-75		42
253	Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. 2015 , 26, 318-25		10
252	Impact of a Performance Improvement CME activity on the care and treatment of patients with psoriasis. 2015 , 72, 516-23		11
251	Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting. 2015 , 42, 1037-1040		2
250	Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic. 2015 , 26, 493-501		19
249	Clinical symptoms and self-reported disease severity among patients with psoriasis - Implications for psoriasis management. 2015 , 26, 514-9		11

248	Nationwide population-based study of cause-specific death rates in patients with psoriasis. 2015 , 29, 1002-5	19
247	Psoriasis and Cardiovascular Disease. 2015 , 99, 1227-42	21
246	Increased risk of aortic valve stenosis in patients with psoriasis: a nationwide cohort study. 2015 , 36, 2177-83	11
245	Aortic valve stenosis: a new cardiovascular comorbidity of psoriasis?. 2015 , 36, 2134-5	2
244	Etiology and Pathogenesis of Psoriasis. 2015 , 41, 665-75	96
243	Psoriasis: More Than Just Skin Deep. 2015 , 35, 2487-8	
242	Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study. 2015 , 277, 447-55	22
241	Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. 2015 , 29, 1128-34	127
240	Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. 2015 , 33, 41-55	107
239	Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. 2015 , 74, 326-32	281
238	Psoriasis and Sleep Apnea: A Danish Nationwide Cohort Study. 2016 , 12, 663-71	22
237	Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. 2016 , 10, 1763-70	21
236	Association Between Psoriasis and Subclinical Atherosclerosis: A Meta-Analysis. 2016 , 95, e3576	31
235	Effect of antipsoriatic therapy on oxidative stress index and sialic acid levels in patients with psoriasis. 2016 , 55, e422-30	9
234	Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). 2016 , 16, 12	28
233	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. 2016 , 75, 83-98.e4	212
232	Do Biologics Protect Patients With Psoriasis From Myocardial Infarction? A Retrospective Cohort. 2016 , 20, 536-541	8
231	Nationwide Study on the Risk of Abdominal Aortic Aneurysms in Patients With Psoriasis. 2016 , 36, 1043-8	15

230	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. 2016 , 43, 1844-1851	8
229	Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. 2016 , 30, 576-85	38
228	Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center. 2016 , 14, 217	21
227	Safety of secukinumab in the treatment of psoriasis. 2016 , 15, 1413-20	75
226	Gastrointestinal comorbidities in patients with psoriatic arthritis. 2016 , 35, 2679-2684	26
225	Lifestyle intervention in psoriasis: a new avenue for treatment?. 2016 , 104, 241-2	
224	Psoriasis Patients Treated With Biologics and Methotrexate Have a Reduced Rate of Myocardial Infarction: A Collaborative Analysis Using International Cohorts. 2016 , 20, 550-554	13
223	Effect of 12-O-tetradecanoylphorbol-13-acetate-induced psoriasis-like skin lesions on systemic inflammation and atherosclerosis in hypercholesterolaemic apolipoprotein E deficient mice. 2016 , 16, 9	16
222	Self-reported depression in psoriasis is associated with subclinical vascular diseases. 2016 , 251, 219-225	20
221	Lipoprotein Metabolism and Inflammation in Patients With Psoriasis. 2016 , 118, 603-9	22
220	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. 2016 , 46, 291-304	84
219	Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis. 2016 , 75, 340-6	13
218	Translating psoriasis guidelines into practice: Important gaps revealed. 2016 , 74, 544-51	3
217	Rhumatisme psoriasique et obésité 2016 , 83, 34-36	
216	Cerebrovascular Disease in Rheumatic Diseases: A Systematic Review and Meta-Analysis. 2016 , 47, 943-50	73
215	Psoriasis and sleep disorders: A systematic review. 2016 , 29, 63-75	72
214	Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis. 2016 , 27, 316-21	26
213	Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile. 2016 , 136, 67-73	29

212	Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives. 2016 , 16, 1-8	14
211	Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. 2017 , 37, 97-105	36
210	Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. 2017 , 69, 67-74	113
209	Recent Highlights in Psoriasis Research. 2017 , 137, 550-556	40
208	Psoriasis and cardiovascular events: updating the evidence. 2017 , 309, 225-228	26
207	Psoriasis and comorbid diseases: Epidemiology. 2017 , 76, 377-390	412
206	Heart and Skin: The Paradigm of Cytokine-Mediated Cardiovascular Metabolic Disease in Psoriasis. 2017 , 263-276	
205	Mortality in patients with psoriasis. A retrospective cohort study. 2017 , 148, 483-488	9
204	Prevalence of coronary artery calcification in Japanese patients with psoriasis: A close correlation with bilateral diagonal earlobe creases. 2017 , 44, 1122-1128	12
203	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. 2017 , 76, 290-298	90
202	Real-world burden of comorbidities in US patients with psoriasis. 2017 , 77, 287-292.e4	46
201	Mortality in patients with psoriasis. A retrospective cohort study. 2017 , 148, 483-488	1
200	Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. 2017 , 37, 775-785	8
199	Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017 , 176, 732-740	4 28
198	Can the skin make you fat? A role for the skin in regulating adipose tissue function and whole-body glucose and lipid homeostasis. 2017 , 37, 59-64	7
197	Cardiometabolic Disorders in Psoriatic Disease. 2017 , 19, 63	18
196	Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. 2017 , 19, 102	66
195	Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. 2017 , 11, 1243-1256	33

194	Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor- α inhibitors versus methotrexate. 2017 , 76, 81-90		72
193	Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. 2017 , 68, 255-269		97
192	Co-morbidity in psoriasis: mechanisms and implications for treatment. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 27-34	5.1	19
191	Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	77
190	Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson's disease is more relevant to bullous pemphigoid. <i>Postepy Dermatologii I Alergologii</i> , 2017 , 34, 42-46	1.5	3
189	Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. 2018 , 79, 345-352		53
188	Psoriasis and cardiovascular disease risk factors: the HUNT Study, Norway. 2018 , 32, 776-782		20
187	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. 2018 , 45, 378-384		27
186	Frequency of Electrocardiographic Abnormalities in Patients With Psoriasis. 2018 , 121, 1004-1007		4
185	Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	27
184	Systemic Therapies in Psoriasis. 2018 , 145-158		
183	Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. 2018 , 32, 2185-2190		7
182	Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?. 2018 , 69, 5-9		1
181	Psoriasis and Atherosclerosis. 2018 , 123, 1183-1184		6
180	Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. 2018 , 1, e183062		31
179	Epidemiology and Immunopathogenesis of Psoriasis and Its Comorbidities. 2018 , 7, 321-329		
178	Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. <i>Frontiers in Immunology</i> , 2018 , 9, 579	8.4	102
177	Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3	62

176	Association Between Psoriasis and Erectile Dysfunction: A Meta-Analysis. 2018 , 15, 839-847		6
175	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018 , 179, 615-622	4	39
174	Psoriasis and Psoriatic Spectrum Disease: A Primer for the Primary Care Physician. 2018 , 131, 1146-1154		6
173	Is the humoral immunity dispensable for the pathogenesis of psoriasis?. 2019 , 33, 115-122		8
172	An Investigation of Comorbid Disease and Health Service Utilization Among Patients With Moderate to Severe Psoriasis in Newfoundland and Labrador. 2019 , 23, 29-34		3
171	Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. 2019 , 39, 1510-1519		36
170	Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: A 15-year nationwide population-based cohort study. 2019 , 46, 859-866		13
169	Coronary Artery Disease Assessed by Computed Tomography in Patients with Psoriasis: A Systematic Review and Meta-Analysis. 2019 , 235, 478-487		14
168	Effects of Online Care on Functional and Psychological Outcomes in Patients with Psoriasis: A Randomized Controlled Trial. 2019 ,		7
167	High burden of the metabolic syndrome and its component disorders in South Africans with psoriasis. 2019 , 58, 557-562		7
166	In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis. 2019 , 21, 36		8
165	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. 2019 , 71, 1651-1659		15
164	All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis. 2019 , 80, 1332-1343	30	
163	Psoriasis and acute coronary syndrome risk. 2019 , 286, 15-16		0
162	Psoriasis Pathogenesis and Treatment. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	427
161	Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. 2019 , 139, e603-e634		108
160	Association of Atherosclerosis Prevalence With Age, Race, and Traditional Risk Factors in Patients With Psoriasis. 2019 , 155, 622-623		2
159	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. 2019 , 80, 1073-1113		145

158	Level of inflammatory cytokines tumour necrosis factor γ (interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome. <i>Postepy Dermatologii I Alergologii</i> , 2019 , 36, 70-75	1.5	3
157	Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. 2019 , 33, 333-339		40
156	Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. 2019 , 80, 27-40		177
155	The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. 2019 , 22, 196-203		11
154	Psoriasis and cardiovascular disease: the elusive link. 2019 , 38, 33-54		13
153	Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. 2020 , 31, 680-686		9
152	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. 2020 , 34, 769-778		18
151	Antibodies towards high-density lipoprotein components in patients with psoriasis. 2020 , 312, 93-102		2
150	Phototherapy decreases red blood cell deformability in patients with psoriasis. 2019 , 73, 489-496		2
149	Psoriasis, cardiovascular risk factors and metabolic disorders: sex-specific findings of a population-based study. 2020 , 34, 779-786		15
148	Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in Psoriasis. 2020 , 133, 267-272		9
147	The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
146	Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020 , 5, 178-183	1.1	
145	Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. 2020 , 22, 254		5
144	Psoriasis and Its Impact on In-Hospital Outcome in Patients Hospitalized with Acute Kidney Injury. 2020 , 9,		1
143	Cardiovascular risk in patients with plaque psoriasis and psoriatic arthritis without a clinically overt cardiovascular disease: the role of endothelial progenitor cells. <i>Postepy Dermatologii I Alergologii</i> , 2020 , 37, 299-305	1.5	0
142	Periodontitis in patients with psoriasis: A systematic review and meta-analysis. 2020 ,		9
141	Pathogenesis of psoriasis in the "omic" era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis. <i>Postepy Dermatologii I Alergologii</i> , 2020 , 37, 452-467	1.5	12

140	Impact of Psoriasis on Mortality Rate and Outcome in Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020 , 9, e016956	6	7
139	Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. 2021 , 60, 2816-2825		3
138	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. 2020 , 323, 1945-1960		268
137	Beyond skin deep: addressing comorbidities in psoriasis. 2020 , 212, 528-534		10
136	Proprotein Convertase Subtilisin/Kexin Type 9, Angiotensin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein-Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
135	Pathogenesis of psoriasis in the "omic" era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances. <i>Postepy Dermatologii i Alergologii</i> , 2020 , 37, 135-153	1.5	11
134	Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. 2020 , 11, 117		32
133	Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report. 2020 , 20, 106		1
132	Potential Role of Atrial Myopathy in the Pathogenesis of Stroke in Rheumatoid Arthritis and Psoriasis: A Conceptual Framework and Implications for Prophylaxis. <i>Journal of the American Heart Association</i> , 2020 , 9, e014764	6	4
131	Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	45
130	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. 2020 , 34, 1695-1706		29
129	Inflammation, Autoimmunity, Infection, and Stroke: Epidemiology and Lessons From Therapeutic Intervention. 2020 , 51, 711-718		28
128	Glycoconjugation as a Promising Treatment Strategy for Psoriasis. 2020 , 373, 204-212		6
127	Comprehensive plaque assessment with serial coronary CT angiography: translation to bedside. 2020 , 36, 2335-2346		5
126	Chronic kidney disease in psoriasis: a cohort study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 438-445	1.2	2
125	Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis. 2021 , 40, 491-499		2
124	Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy. 2021 , 313, 255-261		
123	Comorbidities in patients with palmoplantar plaque psoriasis. 2021 , 84, 639-643		4

122	CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. 2021 , 84, 913-920		6
121	Smoking habits amongst patients with psoriasis and the effect of smoking on clinical and treatment-associated characteristics: A cross-sectional study. 2021 , 75, e13751		0
120	Enhanced Inflammasome Activity in Patients with Psoriasis Promotes Systemic Inflammation. 2021 , 141, 586-595.e5		16
119	Innate Immune Mechanisms of Arterial Hypertension and Autoimmune Disease. 2021 , 34, 143-153		1
118	Wirksamkeit und Sicherheit von Biologika bei Psoriasis und Psoriasis-Arthritis und ihre Auswirkungen auf Komorbiditäten: eine Literaturübersicht. 2021 , 9, 2-8		
117	Prevention of Cardiovascular Disease. 2021 , 33-54		
116	The Importance of Cardiac Assessment in the Era of Biologic Therapies for Psoriasis. 2021 , 419-430		
115	Association of Metabolic Comorbidities with Pediatric Psoriasis: A Systematic Review and Meta-Analysis. 2021 , 33, 203-213		2
114	Assessment of the economic burden and the current state of the drug provision organization for patients with psoriasis in the Russian Federation. <i>Klinicheskaya Dermatologiya I Venerologiya</i> , 2021 , 20, 8	0.3	
113	Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis: An Italian Study.. 2022 , 28, e324-e329		1
112	Osteopontin Serum Concentration and Metabolic Syndrome in Male Psoriatic Patients. 2021 , 10,		2
111	Psoriasis: Comorbidities. 2021 , 48, 732-740		10
110	Multiscale Biology of Cardiovascular Risk in Psoriasis: Protocol for a Case-Control Study (Preprint).		
109	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. 2021 , 14, 2212-2220		8
108	Association between Vascular Inflammation and Inflammation in Adipose Tissue, Spleen, and Bone Marrow in Patients with Psoriasis. <i>Life</i> , 2021 , 11,	3	5
107	The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study. <i>Scientific Reports</i> , 2021 , 11, 8588	4.9	0
106	Psoriasis Severity and Cardiometabolic Risk Factors in a Representative US National Study. 2021 , 22, 719-730		0
105	Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. 2021 , 1-36		1

104	Trimethylamine N-Oxide, a Gut Microbiota-Derived Metabolite, Is Associated with Cardiovascular Risk in Psoriasis: A Cross-Sectional Pilot Study. 2021 , 11, 1277-1289		4
103	Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020. 2021 , 40, 4061-4070		2
102	Guidelines for Management of Psoriasis. 2021 , 13, 168-174		1
101	A soft voting ensemble classifier for early prediction and diagnosis of occurrences of major adverse cardiovascular events for STEMI and NSTEMI during 2-year follow-up in patients with acute coronary syndrome. <i>PLoS ONE</i> , 2021 , 16, e0249338	3.7	9
100	[Obesity - A Risk Factor for Psoriasis and COVID-19]. <i>Actas Dermo-sifiliográficas</i> , 2021 , 112, 489-494	0.5	1
99	microRNAs involved in psoriasis and cardiovascular diseases. 2021 , 3, R49-R68		2
98	Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. 2021 , 40, 4933-4942		2
97	Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function. 2021 , 1866, 158943		1
96	Relation of therapies for ankylosing spondylitis and psoriatic arthritis to risk of myocardial infarction: a nested case control study. 2021 , 5, 36		0
95	Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk. <i>Frontiers in Immunology</i> , 2021 , 12, 688864	8.4	0
94	Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. 2021 , 21, 1291-1298		3
93	Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies. 2021 , 5, 783-794		3
92	Psoriasis Prevalence in Adults in the United States. 2021 , 157, 940-946		20
91	Cardiovascular Risk Associated with Methotrexate versus Retinoids in Patients with Psoriasis: A Nationwide Taiwanese Cohort Study. 2021 , 13, 693-705		1
90	A transcriptome-wide association study identifies novel susceptibility genes for psoriasis. 2021 ,		1
89	Association of lichen planus with cardiovascular disease: A combined analysis of the UK Biobank and All of Us Study. 2021 ,		1
88	Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism. 2021 , 343, 114-121		0
87	Multiscale Biology of Cardiovascular Risk in Psoriasis: Protocol for a Case-Control Study. 2021 , 10, e28669		2

86	Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. 2021 , 335, 98-109		0
85	Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients. <i>Life</i> , 2021 , 11,	3	2
84	Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. 2021 , 11, 385-400		7
83	Down syndrome, severe psoriasis, and increased risk for cardiovascular events. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2019 , 32, 31-33	0.8	5
82	RAC1 activation drives pathologic interactions between the epidermis and immune cells. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2661-77	15.9	39
81	Impaired heart rate recovery indices in psoriasis patients. <i>Medical Science Monitor</i> , 2014 , 20, 350-4	3.2	4
80	Diacerein inhibits the pro-atherogenic & pro-inflammatory effects of IL-1 on human keratinocytes & endothelial cells. <i>PLoS ONE</i> , 2017 , 12, e0173981	3.7	12
79	An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. <i>PLoS ONE</i> , 2017 , 12, e0181039	3.7	55
78	[Cardiovascular risk in patients with psoriatic arthritis]. <i>Terapevticheskii Arkhiv</i> , 2016 , 88, 102-106	0.9	5
77	Cardiovascular Risk in Psoriasis: Current State of the Art. <i>Current Vascular Pharmacology</i> , 2019 , 17, 85-91	3.3	17
76	Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives. <i>Current Vascular Pharmacology</i> , 2020 , 18, 592-609	3.3	3
75	Prevalence of Metabolic Syndrome in Psoriasis and Levels of Interleukin-6 and Tumor Necrosis Factor- α in Psoriasis Patients with Metabolic Syndrome: Indian Tertiary Care Hospital Study. <i>International Journal of Applied & Basic Medical Research</i> , 2017 , 7, 169-175	1.1	8
74	Advanced Glycation End Products, a Potential Link between Psoriasis and Cardiovascular Disease: A Case-control Study. <i>Indian Journal of Dermatology</i> , 2019 , 64, 201-206	0.9	8
73	Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort). <i>Indian Journal of Endocrinology and Metabolism</i> , 2017 , 21, 581-587	1.7	11
72	Targeting the Inflammation Culprit in Patients with Psoriasis/Psoriatic Arthritis and Associated Cardiovascular Comorbidities. Is the IL-17 Inhibitor the New Kid on the Block?. <i>World Journal of Cardiovascular Diseases</i> , 2019 , 09, 267-294	0	1
71	Double trouble: psoriasis and cardiometabolic disorders. <i>Cardiovascular Journal of Africa</i> , 2018 , 29, 189-194	0.4	3
70	Association of C-Reactive Protein (rs1205) Gene Polymorphism with Susceptibility to Psoriasis in South Indian Tamils. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016 , 10, GC01-GC04	0	4
69	Atherosclerosis attacks in patients with psoriasis vulgaris but without a relationship with the severity and course of the disease. <i>Postepy Dermatologii I Alergologii</i> , 2021 , 38, 673-681	1.5	0

68	Neutrophil Pathways of Inflammation Characterize the Blood Transcriptomic Signature of Patients with Psoriasis and Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
67	Risk of infections in psoriasis: assessment and challenges in daily management. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1211-1220	5.1	1
66	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2021 ,	4	4
65	Evaluation of ventricular repolarization features with novel electrocardiographic parameters (Tp-e, Tp-e/QT) in patients with psoriasis. <i>Anatolian Journal of Cardiology</i> , 2017 , 18, 397-401	0.8	7
64	Psoriasis. 2019 , 139-154		
63	Chronische Nierenerkrankung bei Psoriasis: eine Kohortenstudie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 438-446	1.2	
62	Psoriasis is an independent predictor of increased risk of allergic reaction during percutaneous coronary interventions. Big data analysis from the Polish National PCI Registry (ORPKI). <i>Cardiology Journal</i> , 2020 , 27, 278-284	1.4	0
61	Obesidad: factor de riesgo para psoriasis y COVID-19. <i>Actas Dermo-sifiliográficas</i> , 2020 ,	0.5	1
60	Psoriasis, psoriatic arthritis, metabolic disorders and cardiovascular disease. What is common?. <i>Klinicheskaya Dermatologiya I Venerologiya</i> , 2020 , 19, 139	0.3	2
59	Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis. <i>Pharmacology & Pharmacy</i> , 2020 , 11, 373-401	0.3	
58	Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade. <i>Vestnik Dermatologii I Venerologii</i> , 2020 , 95, 68-77	0.4	
57	How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials. <i>Postepy Dermatologii I Alergologii</i> , 2020 , 37, 986-994	1.5	0
56	Biomarkers of subclinical atherosclerosis in patients with psoriasis. <i>Scientific Reports</i> , 2021 , 11, 21438	4.9	3
55	Myopenia and Musculoskeletal Aging in Rheumatoid Arthritis.		
54	Hypertension in psoriasis patients: based on office and ambulatory blood pressure measurement. <i>Blood Pressure Monitoring</i> , 2020 , 25, 351-354	1.3	
53	Psoriasis and Comorbidities. 2021 , 363-397		
52	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014 , 7, S5-S22	1.2	
51	Examining Dermatologist Use and Opinions of Ultraviolet Radiation for Cosmetic and Medical Purposes. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2018 , 11, 41-46	1.2	1

50	Skin and Metabolic Syndrome: An Evidence Based Comprehensive Review. <i>Indian Journal of Dermatology</i> , 2021 , 66, 302-307	0.9	0
49	Comorbidities and Systemic Associations. 2022 , 69-76		
48	The Digital Way to Intercept Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2021 , 8, 792972	4.9	2
47	Nailfold videocapillaroscopy identifies microvascular pathologies in psoriasis vulgaris: Results of a prospective controlled study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 1736-1744	1.2	3
46	Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. <i>Rheumatology and Therapy</i> , 2021 , 1	4.4	0
45	IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
44	Epidemiology of psoriasis in the Russian Federation according to the patient registry. <i>Vestnik Dermatologii I Venerologii</i> , 2021 , 98, 33-41	0.4	1
43	Can Biological Drugs Diminish the Risk of Sarcopenia in Psoriatic Patients? A Systematic Review.. <i>Life</i> , 2022 , 12,	3	
42	Psoriasis and Cardiovascular Risk in Children: The Usefulness of Carotid Intima-Media Thickness.. <i>Pediatric Cardiology</i> , 2022 , 1	2.1	0
41	Cardiovascular diseases in patients with psoriasis in clinical practice: case report. <i>Eurasian Heart Journal</i> , 2022 , 94-99	0.7	
40	Pharmacological management of severe plaque psoriasis in patients with cardiovascular disease.. <i>Expert Opinion on Pharmacotherapy</i> , 2022 ,	4	1
39	Psoriasis and risk of myocardial infarction: Uncertain link, costly implications.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	
38	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement.. <i>American Journal of Preventive Cardiology</i> , 2022 , 10, 100335	1.9	3
37	Mikrovaskuläre Pathologien bei Patienten mit Psoriasis vulgaris mittels Nagelfalzkapillarmikroskopie identifiziert: Ergebnisse einer prospektiven kontrollierten Studie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 1736-1745	1.2	
36	Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention. <i>Contemporary Cardiology</i> , 2022 , 247-270	0.1	1
35	Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab. <i>Serbian Journal of Experimental and Clinical Research</i> , 2022 ,	0.3	
34	Marcha psoriásica: una mirada desde la fisiopatología hasta el riesgo cardiovascular. <i>Revista Colombiana De Reumatología</i> , 2022 ,	0.2	
33	Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	0

32	Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living With Psoriatic Disease. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 247553032211018	1.1	0
31	Endothelial Dysfunction in Psoriasis: An Updated Review. <i>Frontiers in Medicine</i> , 9,	4.9	0
30	THE ROLE OF INFLAMMATION AND THE POSSIBILITIES OF INFLAMMATION REDUCTION TO PREVENT CARDIOVASCULAR EVENTS. <i>European Heart Journal Open</i> ,		2
29	Oxidative Stress Induced by High Salt Diet Possible Implications for Development and Clinical Manifestation of Cutaneous Inflammation and Endothelial Dysfunction in Psoriasis vulgaris. <i>Antioxidants</i> , 2022, 11, 1269	7.1	0
28	Incidence and prevalence of psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in Teleprimary Care (TPC) clinical information system from 2010 to 2020. <i>British Journal of Dermatology</i> ,	4	
27	The risk of organ-based comorbidities in psoriasis: a systematic review and meta-analysis. <i>Anais Brasileiros De Dermatologia</i> , 2022,	1.6	0
26	Otologic Manifestations of Psoriasis: A Systematic Review and Meta-Analysis. <i>Otology and Neurotology</i> , 2022, 43, 742-752	2.6	
25	Case-Fatality and Temporal Trends in Patients with Psoriasis and End-Stage Renal Disease. 2022, 11, 4328		0
24	Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review.		0
23	Risk for incident suicidality among psoriasis patients: a systematic review and meta-analysis.		0
22	Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways. 2022, 23, 9063		0
21	Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors.		1
20	Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients. 2022, 57, 152096		2
19	Biomarkers of inflammation and left ventricular remodelling in psoriasis patients treated with infliximab. 2022, 36, 039463202211111		0
18	Prevention and risk assessment of cardiovascular events in a population of patients with psoriasis and psoriatic arthritis. 2022, 60, 266-274		0
17	Psoriatic erythroderma: comparative patient profile and association with psoriatic arthritis.		0
16	Body Composition, Cardiometabolic Risk Factors and Comorbidities in Psoriasis and the Effect of HLA-C*06:02 Status: The HUNT Study, Norway.		0
15	Potential Cerebrovascular Accident Signal for Risankizumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS).		0

14	2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities. 2022 ,	0
13	Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis. 9,	0
12	Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).	0
11	The cardiometabolic safety of interleukin 23 versus interleukin 17 inhibitors in psoriasis: A large-scale global cohort study.	0
10	Early intervention in psoriasis: Where do we go from here?. 9,	0
9	Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients. 2022 , 12, 1870	1
8	Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. 2023 , 12, 1162	0
7	Lack of association between vitiligo and major adverse cardiovascular events: A population-based cohort study.	0
6	Psoriasis y riesgo cardiovascular. 2023 ,	0
5	Knowledge Mapping and Research Hotspots of Comorbidities in Psoriasis: A Bibliometric Analysis from 2004 to 2022. 2023 , 59, 393	0
4	Quantitative proteomic analysis of human serum using tandem mass tags to predict cardiovascular risks in patients with psoriasis. 2023 , 13,	0
3	The SELP, CD93, IL2RG, and VAV1 Genes Associated with Atherosclerosis May Be Potential Diagnostic Biomarkers for Psoriasis. Volume 16, 827-843	0
2	COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study. 14,	0
1	Cardiovascular Disease and Cardiac Imaging in Inflammatory Arthritis. 2023 , 13, 909	0